Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Safety and Efficacy of Systemic Allogenic NK Cells in R/R Neuroblastoma — Stella

Home/Neuroblastoma, Recurrent, Refractory/

View on ClinicalTrials.gov

Recruiting

Back to Neuroblastoma, Recurrent, Refractory trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

Iran

Rasoul Akram Hospital, Tehran

Key details

Phase

Early testing

Sponsor

Marzieh Ebrahimi

Collaborators

Royan Institute, Iran University of Medical Sciences

Enrollment target

~10 participants

Started

November 2024

Primary completion

November 2026

Age range

2 Years – 16 Years

Last updated April 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.